In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018

A look at the financing, M&A and alliance activity in January-March 2018

Executive Summary

Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.

Advertisement

Related Content

Varian Stands Firm Against Rival Bid For SirTex; What Next If It All Falls Down?
'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy
Boston Scientific Scores March M&A Double Whammy With NxThera
J&J Offloads LifeScan To Private Equity Firm For $2.1bn
Siemens Healthineers Floats On Frankfurt Stock Exchange
Roche To Improve Real-World Cancer Data Extraction With Flatiron Buy
LivaNova To Buy TandemLife For Up to $250m, Adding Complementary Cardiac Surgery
Varian To Pay $1.3bn For Interventional Oncology Specialist Sirtex
FIRE1 Stokes Up €40m New Capital
Device Debut: Procept Biorobotics Expects To Make A Splash With AquaBeam

Topics

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel